You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
Login
Username:

Password:


Related Headlines

Lupin launches Dasatinib tablets in US market

WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals

Natera submits Signatera CDx PMA to FDA for bladder cancer use

Pharming receives FDA complete response letter for paediatric Joenja application

Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer

I Peace generates human iPS cells from NKT cells and offers them for research use

Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA

Frontage expands early phase clinical research capabilities across US and China

AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC

Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat

Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir

MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA

FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia

Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA

OSE Immunotherapeutics prioritises pouchitis and hidradenitis suppurativa for lusvertikimab development

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026